Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL2846 in iodine-refractory differentiated thyroid cancer after TKI failure
NCT05745363Phase 2Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Feb 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vilzemetkib in differentiated thyroid cancer (DTC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Objective Response Rate at 12 months. Started Feb 2023; status: completed.
02
Drugs
vilzemetkib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT05745363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05745363.